FHIT loss confers cisplatin resistance in lung cancer via the AKT|[sol]|NF-|[kappa]|B|[sol]|Slug-mediated PUMA reduction

Correction to: Oncogene (2015) 34, 2505−2515; doi:10.1038/onc.2014.184; published online 7 July 2014 Since the publication of the above article, the authors have noticed that the PUMA immunostainings in the ‘A549 (NC) treated with cisplatin’ panels in Figure 4c was incorrect. The authors acknowledged this was the result of administrative error and have provided the correct images for the affected panels.